Blood test identifies key Alzheimer's marker

July 19, 2017 by Tamara Bhandari, Washington University School of Medicine
Credit: Washington University School of Medicine

A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their brains or cerebrospinal fluid. Currently, the only way to detect amyloid beta in the brain is via PET scanning, which is expensive and not widely available, or a spinal tap, which is invasive and requires a specialized medical procedure.

Decades before with Alzheimer's disease develop memory loss and confusion, their brains become dotted with plaques made of a sticky protein - called amyloid beta - that is thought to contribute to the disease and its progression.

Currently, the only way to detect amyloid beta in the is via PET scanning, which is expensive and not widely available, or a spinal tap, which is invasive and requires a specialized . But now, a study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the have the potential to help identify people with altered levels of amyloid in their brains or .

Ideally, a blood-based screening test would identify people who have started down the path toward Alzheimer's years before they could be diagnosed based on symptoms.

"Our results demonstrate that this amyloid beta blood test can detect if amyloid has begun accumulating in the brain," said Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology and the study's senior author. "This is exciting because it could be the basis for a rapid and inexpensive blood screening test to identify people at high risk of developing Alzheimer's disease."

The findings will be announced July 19 at the Alzheimer's Association International Conference in London and published online in the journal Alzheimer's and Dementia.

As the brain engages in daily tasks, it continually produces and clears away amyloid beta. Some is washed into the blood, and some floats in the cerebrospinal fluid, for example. If amyloid starts building up, though, it can collect into plaques that stick to neurons, triggering neurological damage.

A blood test would be cheaper and less invasive than PET scans or spinal taps, but previous studies have found that measures of total levels of amyloid beta in the blood don't correlate with levels in the brain.

So Bateman and colleagues measured blood levels of three amyloid subtypes - amyloid beta 38, amyloid beta 40 and amyloid beta 42—using highly precise measurement by mass spectrometry to see if any correlated with levels of amyloid in the brain.

The researchers studied 41 people ages 60 and older. Twenty-three were amyloid-positive, meaning they had signs of cognitive impairment. PET scans or spinal taps in these patients also had detected the presence of in the brain or amyloid alterations in the cerebrospinal fluid. The researchers also measured amyloid subtypes in 18 people who had no buildup of amyloid in the brain.

To measure amyloid levels, production and clearance over time, the researchers drew 20 blood samples from each person over a 24-hour period. They found that levels of amyloid beta 42 relative to amyloid beta 40 were consistently 10 to 15 percent lower in the people with amyloid plaques.

"Amyloid plaques are composed primarily of amyloid beta 42, so this probably means that it is being deposited in the brain before moving into the bloodstream," Bateman said.

"The differences are not big, but they are highly consistent," he explained. "Our method is very sensitive, and particularly when you have many repeated samples as in this study—more than 500 samples overall—we can be highly confident that the difference is real. Even a single sample can distinguish who has amyloid plaques."

By averaging the ratio of amyloid beta 42 to 40 over each individual's 20 samples, the researchers could classify people accurately as amyloid-positive or -negative 89 percent of the time. On average, any single time point was also about 86 percent accurate.

Amyloid plaques are one of the two characteristic signs of Alzheimer's disease; the other sign is the presence of tangles of a brain protein known as tau. David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology at the School of Medicine, is developing a blood-based test for tau that could complement the test.

"If we had a for tau as well, we could combine them to get an even better idea of who is most at risk of developing Alzheimer's disease," Bateman said. "That would be a huge step forward in our ability to predict, and maybe even prevent, Alzheimer's disease."

Explore further: Brain's ability to dispose of key Alzheimer's protein drops dramatically with age

More information: Ovod V, Bollinger JG, Mawuenyega KG, Hicks TJ, Schneider T, Kasten T, Sigurdson W, Sullivan M, Donahue TA, Ramsey K, Paumier K, Holtzman DM, Morris JC, Benzinger TLS, Fagan AM, Patterson BW, and Bateman RJ. Concentrations and Stable Isotope Label Kinetics of Human Plasma Amyloid Beta. Alzheimer's Association International Conference. Oral presentation. July 19, 2017.

Ovod V, Ramsey K, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson B, and Bateman RJ. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to CNS amyloidosis. Alzheimer's and Dementia. July 19, 2017.

Related Stories

Brain's ability to dispose of key Alzheimer's protein drops dramatically with age

July 31, 2015
The greatest risk factor for Alzheimer's disease is advancing age. After 65, the risk doubles every five years, and 40 percent or more of people 85 and older are estimated to be living with the devastating condition.

Never before seen images of early stage Alzheimer's disease

March 13, 2017
Researchers at Lund University in Sweden have used the MAX IV synchrotron in Lund – the strongest of its kind in the world - to produce images that predate the formation of toxic clumps of beta-amyloid, the protein believed ...

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Alzheimer's brain change measured in humans

June 12, 2013
Scientists at Washington University School of Medicine in St. Louis have measured a significant and potentially pivotal difference between the brains of patients with an inherited form of Alzheimer's disease and healthy family ...

In elderly, hardening of arteries linked to plaques in brain

October 16, 2013
Even for elderly people with no signs of dementia, those with hardening of the arteries are more likely to also have the beta-amyloid plaques in the brain that are a hallmark of Alzheimer's disease, according to a study published ...

Recommended for you

Data detectives shift suspicions in Alzheimer's to inside villain

February 20, 2018
The mass pursuit of a conspicuous suspect in Alzheimer's disease may have encumbered research success for decades. Now, a new data analysis that has untangled evidence amassed in years of Alzheimer's studies encourages researchers ...

Not being aware of memory problems predicts onset of Alzheimer's disease

February 15, 2018
Doctors who work with individuals at risk of developing dementia have long suspected that patients who do not realize they experience memory problems are at greater risk of seeing their condition worsen in a short time frame, ...

Researchers successfully reverse Alzheimer's disease in mouse model

February 14, 2018
A team of researchers from the Cleveland Clinic Lerner Research Institute have found that gradually depleting an enzyme called BACE1 completely reverses the formation of amyloid plaques in the brains of mice with Alzheimer's ...

Poor fitness linked to weaker brain fiber, higher dementia risk

February 14, 2018
Scientists have more evidence that exercise improves brain health and could be a lifesaving ingredient that prevents Alzheimer's disease.

Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer's disease

February 7, 2018
The supplement nicotinamide riboside (NR) – a form of vitamin B3 – prevented neurological damage and improved cognitive and physical function in a new mouse model of Alzheimer's disease. The results of the study, conducted ...

Positive attitudes about aging reduce risk of dementia in older adults

February 7, 2018
Research has shown that older persons who have acquired positive beliefs about old age from their surrounding culture are less likely to develop dementia. This protective effect was found for all participants, as well as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.